Request Demo
Last update 02 Sep 2025
Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Last update 02 Sep 2025
Overview
Basic Info
Drug Type Oncolytic virus |
Synonyms Ad-TD-nsIL12, BioTTT001 |
Target |
Action stimulants |
Mechanism IL-12R stimulants(Interleukin-12 receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)NCT07126990
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
NCT06763965
A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Recurrent/progressive High-grade Glioma.
NCT06215846
Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Malignant Solid Tumors
100 Clinical Results associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Translational Medicine associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Patents (Medical) associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Deals associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| High grade glioma | Phase 2 | China | 26 Nov 2024 | |
| Recurrent Malignant Glioma | Phase 2 | China | 26 Nov 2024 | |
| Metastatic Gastric Carcinoma | Phase 2 | - | 02 Apr 2024 | |
| Secondary malignant neoplasm of peritoneum | Phase 2 | - | 02 Apr 2024 | |
| Locally advanced breast cancer | Phase 1 | China | 26 Mar 2025 | |
| Colorectal Cancer | Phase 1 | China | 07 May 2024 | |
| Head and Neck Neoplasms | Phase 1 | China | 07 May 2024 | |
| Skin Neoplasms | Phase 1 | China | 07 May 2024 | |
| Uterine Cervical Cancer | Phase 1 | China | 07 May 2024 | |
| Colorectal Liver Metastases | Phase 1 | - | 02 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | Peritoneal Neoplasms CA125 levels | 9 | BioTTT001 5×10^9vp | vtpsddovgo(fcxisnkslc) = yunumjemen voqmieguix (dicspmiskz ) View more | Positive | 30 May 2025 | |
BioTTT001 5×10^10vp | vtpsddovgo(fcxisnkslc) = anakygukms voqmieguix (dicspmiskz ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free